Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorPINHEIRO, W.-
dc.contributor.authorPEREIRA, A. K. Cavalcante-
dc.contributor.authorSOARES JR., J. M.-
dc.contributor.authorBARACAT, E. C.-
dc.identifier.citationEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, v.32, n.1, p.37-39, 2011-
dc.description.abstractObjective: To determine the effectiveness of the combination of mitomycin C, bleomycin and methotrexate as a neoadjuvant treatment in preparation for surgical treatment of cervical cancer. Methods and Materials: Twenty-seven patients with carcinoma of the uterine cervix (stages exophytic IB2 and IIB-IIIB) who had not previously undergone any treatment received mitomycin C, bleomycin and methotrexate in five sessions, once every four weeks. Results: The objective response rate was approximately 81%, including 16 complete responses and six partial responses. Significant toxic effects were not observed. Responsive patients underwent surgery and remained without evidence of disease for the next 20 years. Unresponsive patients did not fare well and passed away within five years after treatment. Conclusion: Our data suggest that this strategy may be effective for advanced cases, enabling patients to receive surgical treatment.-
dc.publisherI R O G CANADA, INC-
dc.relation.ispartofEuropean Journal of Gynaecological Oncology-
dc.subjectCervical cancer-
dc.subject.otheruterine cervix-
dc.subject.othercell carcinoma-
dc.titleIs the combination of mitomycin C, bleomycin and methotrexate effective as a neoadjuvant treatment for cervical cancer in women?-
dc.rights.holderCopyright I R O G CANADA, INC-
dc.subject.wosObstetrics & Gynecology-
dc.type.categoryoriginal article-
hcfmusp.relation.referenceMonk BJ, 2007, GYNECOL ONCOL, V105, P427, DOI 10.1016/j.ygyno.2006.12.027-
hcfmusp.relation.referenceKIM DS, 1988, GYNECOL ONCOL, V29, P321, DOI 10.1016/0090-8258(88)90231-4-
hcfmusp.relation.referenceChen J, 2008, OBSTET GYNECOL, V111, P1394, DOI 10.1097/AOG.0b013e318173570b-
hcfmusp.relation.referenceSherris J, 2001, WESTERN J MED, V175, P231, DOI 10.1136/ewjm.175.4.231-
hcfmusp.relation.referencePerez CA, 1998, INT J RADIAT ONCOL, V41, P307, DOI 10.1016/S0360-3016(98)00067-4-
hcfmusp.relation.referenceBoruta DM, 2001, GYNECOL ONCOL, V81, P82, DOI 10.1006/gyno.2000.6118-
hcfmusp.relation.referenceFRIEDLANDER ML, 1984, GYNECOL ONCOL, V19, P1, DOI 10.1016/0090-8258(84)90150-1-
hcfmusp.relation.referenceGray Heidi J, 2008, J Natl Compr Canc Netw, V6, P47-
hcfmusp.relation.referenceIsonishi S, 1996, Gan To Kagaku Ryoho, V23, P1896-
hcfmusp.relation.referenceKokawa K, 2007, ANTICANCER RES, V27, P2721-
hcfmusp.relation.referenceMUSCATO MS, 1982, SEMIN ONCOL, V9, P373-
hcfmusp.relation.referencePecorelli S, 2003, CANCER J, V9, P390, DOI 10.1097/00130404-200309000-00009-
hcfmusp.relation.referenceRUSTIN GJS, 1987, BRIT J OBSTET GYNAEC, V94, P1205, DOI 10.1111/j.1471-0528.1987.tb02323.x-
hcfmusp.relation.referenceSismondi P, 1985, Minerva Ginecol, V37, P27-
hcfmusp.relation.referenceTierney JF, 2008, CLIN ONCOL-UK, V20, P401, DOI 10.1016/j.clon.2008.04.003-
hcfmusp.relation.referenceUmezawa K, 1999, ADV ENZYME REGUL, V39, P145, DOI 10.1016/S0065-2571(98)00022-3-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.